{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:30:54Z","timestamp":1789637454198,"version":"4.0.0"},"reference-count":33,"publisher":"Japan Atherosclerosis Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,2,1]]},"DOI":"10.5551\/jat.64809","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T18:10:25Z","timestamp":1725387025000},"page":"239-252","source":"Crossref","is-referenced-by-count":13,"title":["FIB-4 Index and Liver Stiffness Measurement are Potential Predictors of Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.5551","volume":"32","author":[{"given":"Yoshihito","family":"Kubotsu","sequence":"first","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Tago","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Chihara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Norita","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Inadomi","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Inoue","sequence":"additional","affiliation":[{"name":"Liver Center, Saga University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Takayanagi","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Isoda","sequence":"additional","affiliation":[{"name":"Liver Center, Saga University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kuwashiro","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Oeda","sequence":"additional","affiliation":[{"name":"Liver Center, Saga University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyasu","family":"Shiratori","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Biliary and Pancreatic Disease, Faculty of Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Anzai","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Node","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University"},{"name":"Liver Center, Saga University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne C, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer D, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot B, Korenjak M, Kowdley K, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell E, Roden M, Romero-G\u00f3mez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology, 2023; 78: 1966-1986","DOI":"10.1097\/HEP.0000000000000520"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology, 2019; 69: 2672-2682","DOI":"10.1002\/hep.30251"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol, 2018; 68: 335-352","DOI":"10.1016\/j.jhep.2017.09.021"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ozturk K, Uygun A, Guler AK, Demirci H, Ozdemir C, Cakir M, Sakin YS, Turker T, Sari S, Demirbas S, Karsl\u0131o\u011flu Y, Saglam M. Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. Atherosclerosis, 2015; 240: 380-386","DOI":"10.1016\/j.atherosclerosis.2015.04.009"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut, 2017; 66: 1138-1153","DOI":"10.1136\/gutjnl-2017-313884"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, Loomba R, Chalasani N, Kowdley K, Hameed B, Wilson LA, Yates KP, Belt P, Lazo M, Kleiner DE, Behling C, Tonascia J. NASH Clinical Research Network (CRN). Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med, 2021; 385: 1559-1569","DOI":"10.1056\/NEJMoa2029349"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2015; 149: 389-397","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther, 2021; 54: 1013-1025","DOI":"10.1111\/apt.16575"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Toh JZK, Pan XH, Tay PWL, Ng CH, Yong JN, Xiao J, Koh JH, Tan EY, Tan EXX, Dan YY, Loh PH, Foo R, Chew NWS, Sanyal AJ, Muthiah MD, Siddiqui MS. A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary Heart Disease in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol, 2022; 20: 2462-2473","DOI":"10.1016\/j.cgh.2021.09.021"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Chen Z, Liu J, Zhou F, Li H, Zhang XJ, She ZG, Lu Z, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. Circ Res, 2021; 128: 1747-1765","DOI":"10.1161\/CIRCRESAHA.121.319059"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol, 2022; 80: 2361-2371","DOI":"10.1016\/j.jacc.2022.11.005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Puchner SB, Lu MT, Mayrhofer T, Liu T, Pursnani A, Ghoshhajra BB, Truong QA, Wiviott SD, Fleg JL, Hoffmann U, Ferencik M. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology, 2015; 274: 693-701","DOI":"10.1148\/radiol.14140933"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yu MM, Tang XL, Zhao X, Chen YY, Xu ZH, Wang QB, Zeng MS. Plaque progression at coronary CT angiography links non-alcoholic fatty liver disease and cardiovascular events: a prospective single-center study. Eur Radiol, 2022; 32: 8111-8121","DOI":"10.1007\/s00330-022-08904-2"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ichikawa K, Miyoshi T, Osawa K, Miki T, Toda H, Ejiri K, Yoshida M, Nakamura K, Morita H, Ito H. Incremental prognostic value of non-alcoholic fatty liver disease over coronary computed tomography angiography findings in patients with suspected coronary artery disease. Eur J Prev Cardiol, 2022; 28: 2059-2066","DOI":"10.1093\/eurjpc\/zwab120"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Simon TG, Roelstraete B, Hagstr\u00f6m H, Sundstr\u00f6m J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut, 2022; 71: 1867-1875","DOI":"10.1136\/gutjnl-2021-325724"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2009; 7: 1104-1112","DOI":"10.1016\/j.cgh.2009.05.033"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K, Le MD, Hooker J, Tu X, Bettencourt R, Yin M, Sirlin CB, Ehman RL, Nakajima A, Loomba R. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol, 2019; 17: 630-637.e8","DOI":"10.1016\/j.cgh.2018.05.059"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Sanyal AJ; American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology, 2002; 123: 1705-1725","DOI":"10.1053\/gast.2002.36572"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Johri AM, Nambi V, Naqvi TZ, Feinstein SB, Kim ESH, Park MM, Becher H, Sillesen H. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. J Am Soc Echocardiogr, 2020; 33: 917-933","DOI":"10.1016\/j.echo.2020.04.021"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, Cal\u00e8s P. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology, 2013; 57: 1182-1191","DOI":"10.1002\/hep.25993"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, Duarte-Rojo A, Wong D, Crotty P, Elkashab M. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int, 2012; 32: 902-910","DOI":"10.1111\/j.1478-3231.2012.02781.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GJ, Nieman K, Pontone G, Raff GL. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr, 2014; 8: 342-358","DOI":"10.1016\/j.jcct.2014.07.003"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Youden WJ. Index for rating diagnostic tests. Cancer, 1950; 3: 32-35","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. Hepatol Res, 2021; 51: 1013-1025","DOI":"10.1111\/hepr.13688"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Niikura T, Imajo K, Ozaki A, Kobayashi T, Iwaki M, Honda Y, Kessoku T, Ogawa Y, Yoneda M, Kirikoshi H, Saito S, Nakajima A. Coronary Artery Disease is More Severe in Patients with Non-Alcoholic Steatohepatitis than Fatty Liver. Diagnostics (Basel), 2020; 10: 129","DOI":"10.3390\/diagnostics10030129"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hagstr\u00f6m H, Nasr P, Ekstedt M, St\u00e5l P, Hultcrantz R, Kechagias S. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol, 2019; 17: 1148-1156","DOI":"10.1016\/j.cgh.2018.11.030"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol, 2018; 68: 335-352","DOI":"10.1016\/j.jhep.2017.09.021"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Cohen DE, Horton JD, Pressman GS, Toth PP. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol, 2022; 42: e168-e185","DOI":"10.1161\/ATV.0000000000000153"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 2020; 69: 1691-1705","DOI":"10.1136\/gutjnl-2020-320622"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Johri AM, Behl P, H\u00e9tu MF, Haqqi M, Ewart P, Day AG, Parfrey B, Matangi MF. Carotid Ultrasound Maximum Plaque Height-A Sensitive Imaging Biomarker for the Assessment of Significant Coronary Artery Disease. Echocardiography, 2016; 33: 281-289","DOI":"10.1111\/echo.13007"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Sillesen H, Sartori S, Sandholt B, Baber U, Mehran R, Fuster V. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. Eur Heart J Cardiovasc Imaging, 2018; 19: 1042-1050","DOI":"10.1093\/ehjci\/jex239"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Tikkanen MJ, Helve E, Nikkil\u00e4 EA. Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol. Eur Heart J, 1987; 8 Suppl E: 97-101","DOI":"10.1093\/eurheartj\/8.suppl_E.97"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism, 2017; 71: 17-32","DOI":"10.1016\/j.metabol.2017.02.014"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/2\/32_64809\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T23:36:48Z","timestamp":1738366608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/2\/32_64809\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.64809","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"article-number":"64809"}}